Risks in new drug development: Approval success rates for investigational drugs

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 5, 2001, Pages 297-307

  DiMasi, Joseph A ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; GASTROINTESTINAL AGENT; IMMUNOLOGIC AGENT; NEW DRUG; RESPIRATORY TRACT AGENT;

CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; HUMAN; NOTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; UNITED STATES;

DATABASES, FACTUAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; PROBABILITY; RESEARCH; TIME FACTORS; UNITED STATES;

EID: 0035338343     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115446     Document Type: Note

References (25)

1. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994;55:609-22.
2. Kaitin KI, Healy EM. The new drug approvals of 1996, 1997, and 1998: Drug development trends in the user fee era. Drug Inf J 2000;34:1-14.
3. Kaitin KI, DiMasi JA. Measuring the pace of new drug development in the user fee era. Drug Inf J 2000;34:673-80.
4. DiMasi JA. New drug innovation and pharmaceutical industry structure: Trends in the output of pharmaceutical firms. Drug Inf J 2000;34:1169-94.
5. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991;10:107-42.
6. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category: A study of the US pharmaceutical industry. Pharmacoecononics 1995;7:152-69.
7. DiMasi J, Grabowski HG, Vernon J. R&D costs, innovative output and firm size in the pharmaceutical industry. Int J Econ Bus 1995;2:201-19.
8. Wardell WM, Hassar M, Anavekar SN, Lasagna L. The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther 1978;24:133-45.
9. Wardell WM, DiRaddo J, Trimble AG. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976. Clin Pharmacol Ther 1980;28:270-7.
10. Wardell WM, May MS, Trimble AG. New drug development by US pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979. Clin Pharmacol Ther 1982;32:407-17.
11. Mattison N, Trimble AG, Lasagna L. New drug development in the United States, 1963 through 1984. Clin Pharmacol Ther 1988;43:290-301.
12. DiMasi JA, Bryant NR, Lasagna L. New drug development in the United States from 1963 to 1990. Clin Pharmacol Ther 1991;50:471-86.
13. US Congress, Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks, and Rewards. Washington: US Government Printing Office, 1993.
14. Tucker SA, Blozan C, Coppinger P. The Outcome of Research on New Molecular Entities Commencing Clinical Research in the Years 1976-79; OPE Study 77. Rockville (MD): US Food and Drug Administration, Office of Planning and Evaluation; 1988.
15. BIenz-Tadmor B, DiCerbo PA, Tadmor G, Lasagna L. Biopharmaceuticals and conventional drugs: Clinical success rates. Biotechnology (NY) 1992;10:521-5.
16. Struck MM. Biopharmaceutical R&D success rates and development times. Biotechnology (NY) 1994;12:674-7.
17. Gosse ME, DiMasi JA, Nelson TF. Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994. Clin Pharmacol Ther 1996;60:608-18.
18. Cox C. A statistical analysis of the success rates and residence times for the IND, NDA and combined phases. In: Lasagna L, Wardell W, Hansen RW, editors. TechnologiCal Innovation and Government Regulation of Pharmaceuticals in the US and Great Britain. A report submitted to the National Science Foundation, August, 1978.
19. Sheck L, Cox C, Davis HT, Trimble AG, Wardell WM, Hansen R. Success rates in the United States drug development system. Clin Pharmacol Ther 1984; 36:574-83.
20. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995;58:1-14.
21. Pharmaprojects. Richmond, Surrey, UK: PJB, 1999.
22. The NDA Pipeline. Chevy Chase (MD): F-D-C Development Corp [various years]; 1983-2000.
23. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 1984.
24. Kane JM. Obstacles to clinical research and new drug development in schizophrenia. Schizophr Bull 1991;17: 353-6.
25. Klein DF. Improvement of phase III psychotropic drug trials by intensive phase II work. Neuropsychopharmacol 1991;4:251-8; discussion 259-71.